The invaders and the barrier

Journal of Hepatology

Volumn 56, Issue 1, 2012, Pages 11-13

  Pawlotsky, Jean Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

AMINO ACID SUBSTITUTION; DRUG EFFICACY; DRUG EXPOSURE; GENETIC BARRIER TO RESISTANCE; HEPATITIS C; HUMAN; IN VIVO FITNESS; IN VIVO STUDY; MEDICAL PARAMETERS; MONOTHERAPY; PRIORITY JOURNAL; REVIEW;

EID: 83555173632     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.09.001     Document Type: Editorial

References (18)

1. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
2. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
3. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
4. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
5. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
6. J.M. Pawlotsky, S. Chevaliez, and J.G. McHutchison The hepatitis C virus life cycle as a target for new antiviral therapies Gastroenterology 132 2007 1979 1998 (Pubitemid 46695724)
7. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, and M. Welker Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777 (Pubitemid 46677938)
8. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, and R.A. Fridell Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
9. J. Mori, J.L. Hammond, S. Srinivasan, S. Jagannatha, and E. van der Ryst Genotypic characterisation of filibuvir (PF-00868554) resistance in patients receiving four weeks co-administration of filibuvir with pegIFN/RBV (12-week analysis) J Hepatol 52 2010 S15
10. S. Le Pogam, A. Seshaadri, A. Ewing, H. Kang, A. Kosaka, and J.M. Yan RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients J Infect Dis 202 2010 1510 1519
11. L. Coelmont, P. Gallay, M. Bobardt, S. Kaptein, J. Paeshuyse, and I. Vliegen Particular in vitro anti-HCV activities and resistance profile of the cyclophylin inhibitor DEBIO-025 J Hepatol 50 2009 S36
12. S. Zeuzem, P. Buggisch, K. Agarwal, M.P. Manns, P. Marcellin, and G.R. Foster Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment-naïve, genotype 1 HCV subjects Hepatology 52 2010 400A
13. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R.H. Ghalib Combination therapy with BMS-790052 and BMS-650032 alone or with PegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders Hepatology 52 2010 877A
14. A. Lok, D. Gardiner, E. Lawitz, C. Martorell, G. Everson, and R. Ghalib Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders J Hepatol 54 2011 S536
15. L. Delang, I. Vliegen, P. Leyssen, and J. Neyts In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors J Hepatol 2011
16. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra32
17. I. Jacobson, P.J. Pockros, J. Lalezari, E. Lawitz, M. Rodriguez-Torres, and E. DeJesus Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2a and ribavirin in chronically-infected HCV genotype 1 patients J Hepatol 52 2010 S465
18. E. Lawitz, I. Jacobson, E. Godofsky, G.R. Foster, R. Flisiak, and M. Bennett A phase 2B trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)/PEG/RBV to 48 weeks treatment with PEG/RBV for chronic genotype 1 HCV infection J Hepatol 54 2011 S181